COMPASS Pathways (NASDAQ:CMPS – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 27th. Analysts expect COMPASS Pathways to post earnings of ...
COMPASS Pathways (NASDAQ:CMPS – Free Report) had its price target reduced by HC Wainwright from $60.00 to $45.00 in a report ...
Shares of Compass Pathways (NASDAQ:CMPS) lost ~35% in the premarket on Thursday after the psychedelic drug developer, with ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, a ...
H.C. Wainwright analyst Patrick Trucchio revised the price target on Compass Pathways (NASDAQ:CMPS) stock, reducing it to $45 ...
H.C. Wainwright lowered the firm’s price target on Compass Pathways (CMPS) to $45 from $60 and keeps a Buy rating on the shares. The firm says ...
Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.
COMPASS Pathways: Institutional Pressure Amid $43M Market Cap Decline, What's Next For This Psychedelics Co? COMPASS Pathways faces $43M market cap loss, raising concerns among institutional ...
RBC Capital analyst Leonid Timashev maintained a Buy rating on COMPASS Pathways (CMPS – Research Report) today and set a price target of $18.00. The company’s shares closed yesterday at $3.36.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results